- Home
- F vs ALNY Comparison
F vs ALNY Comparison
Compare F & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- F
- ALNY
- Stock Information
- Founded
- F 1903
- ALNY 2002
- Country
- F United States
- ALNY United States
- Employees
- F N/A
- ALNY N/A
- Industry
- F Auto Manufacturing
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- F Consumer Discretionary
- ALNY Health Care
- Exchange
- F Nasdaq
- ALNY Nasdaq
- Market Cap
- F 40.9B
- ALNY 39.6B
- IPO Year
- F N/A
- ALNY 2004
- Fundamental
- Price
- F $10.60
- ALNY $309.70
- Analyst Decision
- F Hold
- ALNY Strong Buy
- Analyst Count
- F 15
- ALNY 25
- Target Price
- F $10.04
- ALNY $324.96
- AVG Volume (30 Days)
- F 100.7M
- ALNY 849.2K
- Earning Date
- F 07-23-2025
- ALNY 07-31-2025
- Dividend Yield
- F 7.08%
- ALNY N/A
- EPS Growth
- F 28.89
- ALNY N/A
- EPS
- F 1.25
- ALNY N/A
- Revenue
- F $182,874,000,000.00
- ALNY $2,348,099,000.00
- Revenue This Year
- F N/A
- ALNY $30.77
- Revenue Next Year
- F $1.14
- ALNY $30.51
- P/E Ratio
- F $8.48
- ALNY N/A
- Revenue Growth
- F 3.03
- ALNY 17.21
- 52 Week Low
- F $8.44
- ALNY $153.23
- 52 Week High
- F $14.85
- ALNY $317.54
- Technical
- Relative Strength Index (RSI)
- F 56.21
- ALNY 63.60
- Support Level
- F $10.38
- ALNY $295.82
- Resistance Level
- F $10.67
- ALNY $317.54
- Average True Range (ATR)
- F 0.21
- ALNY 7.74
- MACD
- F 0.01
- ALNY -0.67
- Stochastic Oscillator
- F 80.90
- ALNY 63.90
About F Ford Motor Company
Ford Motor Co. manufactures automobiles under its Ford and Lincoln brands. In March 2022, the company announced that it will run its combustion engine business, Ford Blue, and its BEV business, Ford Model e, as separate businesses but still all under Ford Motor. The company has nearly 13% market share in the United States, about 10% share in the UK, and under 2% share in China including unconsolidated affiliates. Sales in the US made up about 68% of 2024 total company revenue. Ford has about 171,000 employees, including about 56,500 UAW employees, and is based in Dearborn, Michigan.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.